Skip to content

Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitis: the CONF-UC Study

Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitis: the CONF-UC Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06624579
Acronym
CONF-UC
Enrollment
26
Registered
2024-10-03
Start date
2024-10-31
Completion date
2026-06-30
Last updated
2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

This study employs a prospective, single-center, interventional design to investigate the prognostic value of confocal endomicroscopy in assessing treatment response in ulcerative colitis (UC) patients receiving small molecules .

Detailed description

The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing. Eligible patients will undergo baseline assessment, including clinical evaluation, partial Mayo score calculation, endoscopic evaluation, biopsies with histological evaluation and confocal endomicroscopy. Follow-up assessments will be conducted at 8 weeks and 6 months after initiating therapy with small molecules . The study aims to enroll a sample size of 26 UC patients to pilot the feasibility and utility of confocal endomicroscopy in assessing barrier dysfunction and treatment response.

Interventions

The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.

Sponsors

FEDERICA FURFARO
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

26 adult subjects with moderate-to-severe active (defined as having patient-reported outcomes, PRO > 2), left-sided or extensive UC, requiring small molecules therapy according to the standards of care (ECCO guidelines) and performing routine investigations with Colonoscopy before starting appropriate therapy, according to the current standard of care indications and ECCO guidelines.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Established diagnosis of UC since at least 12 weeks prior to inclusion 2. Age ≥ 18 years 3. Any gender/sex 4. Active disease consistent with indication to start with Small molecules (defined as Mayo endoscopic score (MES) ≥ 1, partial Mayo score ≥ 3 (with at least rectal bleeding score of 1 and bowel movements score of 1) 5. No contraindications to endoscopy or confocal exam 6. Ability to understand and to comply with the study procedure and sign an informed consent form

Exclusion criteria

1. Subjects with an endoscopic Mayo sub-score at baseline <2; 2. Pregnancy 3. Subjects with any contraindication to any study procedure (included fluorescein allergy).

Design outcomes

Primary

MeasureTime frameDescription
Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitisat 8 weeks and 6 months to treatment initiationThe study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.

Contacts

Primary ContactFEDERICA FURFARO GASTROENTEROLOGIST
furfaro.federica@hsr.it0039+0226432069

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026